866-997-4948(US-Canada Toll Free)

Colorectal Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 384 Pages


Global Markets Directs, \'Colorectal Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colorectal Cancer. 

Colorectal Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Colorectal Cancer.
  • A review of the Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Colorectal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Colorectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Colorectal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Colorectal Cancer Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Colorectal Cancer 14
Colorectal Cancer Therapeutics under Development by Companies 16
Colorectal Cancer Therapeutics under Investigation by Universities/Institutes 24
Late Stage Products 40
Comparative Analysis 40
Mid Clinical Stage Products 41
Comparative Analysis 41
Early Clinical Stage Products 42
Comparative Analysis 42
Discovery and Pre-Clinical Stage Products 43
Comparative Analysis 43
Colorectal Cancer Therapeutics Products under Development by Companies 44
Colorectal Cancer Therapeutics Products under Investigation by Universities/Institutes 54
Companies Involved in Colorectal Cancer Therapeutics Development 85
Johnson & Johnson 85
F. Hoffmann-La Roche Ltd. 86
Kyowa Hakko Kirin Co., Ltd. 87
Abbott Laboratories 88
Amgen Inc. 89
AstraZeneca PLC 90
Eli Lilly and Company 91
Viralytics Ltd. 92
GlaxoSmithKline plc 93
Tekmira Pharmaceuticals Corp. 94
Nektar Therapeutics 95
Gilead Sciences, Inc. 96
Daiichi Sankyo Company, Ltd 97
AbGenomics International, Inc. 98
Oxford BioMedica plc 99
YM BioSciences Inc. 100
Celltrion, Inc. 101
BioSante Pharmaceuticals, Inc. 102
Novartis AG 103
Aphios Corporation 104
Astellas Pharma Inc. 105
DanDrit Biotech A/S 150
Merrimack Pharmaceuticals, Inc. 151
CritiTech, Inc. 152
Advenchen Laboratories, LLC 153
MolMed S.p.A. 154
Globeimmune, Inc. 155
Etubics Corporation 156
CG Therapeutics, Inc. 157
Quintessence Biosciences, Inc. 158
Kinex Pharmaceuticals, LLC 159
CureTech Ltd. 160
Lipopharma 161
Nereus Pharmaceuticals, Inc. 162
AVEO Pharmaceuticals, Inc. 163
Cancer Therapeutics CRC Pty Ltd 164
Jiangsu Kanion Pharmaceutical Co., Ltd. 165
VectorLogics, Inc. 166
ISA Pharmaceuticals B.V. 167
Regulon Inc. 168
Gradalis Inc. 169
Colorectal Cancer Therapeutics Assessment 170
Assessment by Monotherapy Products 170
Assessment by Combination Products 171
Assessment by Route of Administration 172
Assessment by Molecule Type 174
Drug Profiles 177
RPI-4610 - Drug Profile 177
GM-CT-01 - Drug Profile 178
Perifosine + Xeloda - Drug Profile 180
aspirin - Drug Profile 182
5-Fluorouracil + Leucovorin Calcium + Oxaliplatin + Bevacizumab - Drug Profile 184
Cetuximab + Xeloda + Eloxa + Avastin - Drug Profile 186
Cetuximab + Capecitabine + Oxaliplatin + Bevacizumab - Drug Profile 188
CAPOX + Bevacizumab - Drug Profile 190
Bev-FOLFOX - Drug Profile 192
FOLF-CB - Drug Profile 194
Erbitux + BMS-582664 - Drug Profile 196
cetuximab - Drug Profile 198
Panitumumab - Drug Profile 199
Fluorouracil + Folinic Acid + Capecitabine - Drug Profile 200
Cetuximab + FOLFIRI - Drug Profile 202
Capecitabine + Bevacizumab - Drug Profile 204
Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan - Drug Profile 205
5-Fluorouracil + L-Leucovorin - Drug Profile 207
Eflornithine + Sulindac - Drug Profile 208
Oxaliplatin + Fluorouracil + Leucovorin Calcium - Drug Profile 209
Lucovorin Calcium + Fluorouracil + Irinotecan - Drug Profile 211
5-Fluorouracil + Interferon Alpha - Drug Profile 213
tegafur + uracil - Drug Profile 214
Fluorouracil + Levamisole Hydrochloride - Drug Profile 215
Fluorouracil + Leucovorin + Levamisole - Drug Profile 216
5-Fluorouracil + Leucovorin + Radiation Therapy - Drug Profile 218
Irinotecan + 5-fluorouracil + Leucovorin - Drug Profile 220
Fluorouracil + Leucovorin Calcium 1 - Drug Profile 221
5-Fluorouracil + Oxaliplatin + Radiation Therapy - Drug Profile 222
FOLFOX - Drug Profile 223
edrecolomab - Drug Profile 225
FOLFOX4 - Drug Profile 226
Oxaliplatin + Fluorouracil + Leucovorin Calcium - Drug Profile 227
FOLFIRI + Cetuximab - Drug Profile 229
Oxaliplatin + Fluorouracil + Leucovorin Calcium + Cetuximab - Drug Profile 231
FOLFOX + Cetuximab - Drug Profile 233
Fluorouracil + Semustine + Vincristine - Drug Profile 235
UFT + Krestin - Drug Profile 237
UFT + Leucovorin - Drug Profile 238
UFT + Leucovorin + Krestin - Drug Profile 239
capecitabine - Drug Profile 241
OxMdG - Drug Profile 242
5-Fluorouracil + OXaliplatin + Folinic Acid - Drug Profile 244
mFOLFOX6 - Drug Profile 245
Tegafur + Uracil + Leucovorin + Polysaccharide-K - Drug Profile 246
FOLFIRI + Bevacizumab - Drug Profile 248
Bevacizumab + FOLFIRI - Drug Profile 250
Uracil-Tegafur + Leucovorin - Drug Profile 251
Hepatic Arterial Infusion 5-FU + FOLFOX + Bevacizumab - Drug Profile 252
FOLFOX + Bevacizumab - Drug Profile 254
Propranolol + Etodolac - Drug Profile 255
rofecoxib - Drug Profile 256
carmofur - Drug Profile 257
Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil - Drug Profile 258
Oxaliplatin + Capecitabine + Radiation Therapy - Drug Profile 260
Fluorouracil + Folinic Acid + Radiation Therapy - Drug Profile 262
Capecitabine + Fluorouracil + Oxaliplatin - Drug Profile 264
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 266
Xelox - Drug Profile 268
Xelox + Bevacizumab - Drug Profile 270
Brivanib + Erbitux - Drug Profile 271
Irinotecan + Capecitabine + Bevacizumab - Drug Profile 273
pioglitazone - Drug Profile 275
5-Fluorouracil + Uracil-Tegafur + Leucovorin - Drug Profile 276
erlotinib hydrochloride - Drug Profile 278
5-Fluorouracil + Capecitabine - Drug Profile 279
Leucovorin + Tegafur + Uracil - Drug Profile 281
Tegafur + Uracil + Krestin - Drug Profile 282
Eloxatin + Xeloda - Drug Profile 283
XELOXA-A - Drug Profile 284
Oxaliplatin + Leucovorin Calcium + 5-FU - Drug Profile 286
Floxuridine + Dexamethasone + Leucovorin - Drug Profile 288
Oxaliplatin + Leucovorin Calcium + Fluorouracil + Celecoxib - Drug Profile 290
Bevacizumab + 5-Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 292
Bevacizumab + Cetuximab + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium + Oxaliplatin - Drug Profile 295
Bevacizumab + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium + Oxaliplatin - Drug Profile 299
Bevacizumab + FOLFOX Regimen + Capecitabine + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 302
Oxaliplatin + 5-Flourouracil + Leucovorin - Drug Profile 305
Capecitabine + Bevacizumab + Irinotecan - Drug Profile 307
FOLFOX Regimen + Fluorouracil + Leucovorin Calcium + Oxaliplatin - Drug Profile 309
5-Fluorouracil + Isovorin - Drug Profile 311
Avastin + Tarceva - Drug Profile 312
CPP-1X + Sulindac - Drug Profile 313
Capecitabine + Bevacizumab - Drug Profile 315
FOLFOX 4 - Drug Profile 316
Ropivacaine + Opioid - Drug Profile 317
Lubiprostone + PEG - Drug Profile 318
Leucovorin + 5-Fluorouracil + Irinotecan + Bevacizumab - Drug Profile 319
Leucovorin + 5-fluorouracil + Irinotecan - Drug Profile 321
Tegafur-Uracil + Leucovorin Calcium - Drug Profile 323
Colorectal Cancer Therapeutics Drug Profile Updates 324
Colorectal Cancer Therapeutics Discontinued Products 330
Colorectal Cancer Therapeutics - Dormant Products 335
Gastric Cancer Product Development Milestones 368
Featured News & Press Releases 368

Appendix 377
Methodology 377
Coverage 377
Secondary Research 377
Primary Research 377
Expert Panel Validation 377
Contact Us 378
Disclaimer 378

List of Table


Number of Products Under Development for Colorectal Cancer, H2 2012 20
Products under Development for Colorectal Cancer Comparative Analysis, H2 2012 21
Number of Products under Development by Companies, H2 2012 23
Number of Products under Development by Companies, H2 2012 (Contd..1) 24
Number of Products under Development by Companies, H2 2012 (Contd..2) 25
Number of Products under Development by Companies, H2 2012 (Contd..3) 26
Number of Products under Development by Companies, H2 2012 (Contd..4) 27
Number of Products under Development by Companies, H2 2012 (Contd..5) 28
Number of Products under Development by Companies, H2 2012 (Contd..6) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 45
Comparative Analysis by Late Stage Development, H2 2012 46
Comparative Analysis by Mid Clinical Stage Development, H2 2012 47
Comparative Analysis by Early Clinical Stage Development, H2 2012 48
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 49
Products under Development by Companies, H2 2012 50
Products under Development by Companies, H2 2012 (Contd..1) 51
Products under Development by Companies, H2 2012 (Contd..2) 52
Products under Development by Companies, H2 2012 (Contd..3) 53
Products under Development by Companies, H2 2012 (Contd..4) 54
Products under Development by Companies, H2 2012 (Contd..5) 55
Products under Development by Companies, H2 2012 (Contd..6) 56
Products under Development by Companies, H2 2012 (Contd..7) 57
Products under Development by Companies, H2 2012 (Contd..8) 58
Products under Development by Companies, H2 2012 (Contd..9) 59
Products under Investigation by Universities/Institutes, H2 2012 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 68
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 69
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 70
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 71
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 72
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 73
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 74
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 75
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 76
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 77
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 78
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 79
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 80
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 81
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 82
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 83
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 84
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 85
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 86
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 87
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 88
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 89
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 90
Johnson & Johnson, H2 2012 91
F. Hoffmann-La Roche Ltd., H2 2012 92
Kyowa Hakko Kirin Co., Ltd., H2 2012 93
Abbott Laboratories, H2 2012 94
Amgen Inc., H2 2012 95
AstraZeneca PLC, H2 2012 96
Eli Lilly and Company, H2 2012 97
Viralytics Ltd., H2 2012 98
GlaxoSmithKline plc, H2 2012 99
Tekmira Pharmaceuticals Corp., H2 2012 100
Nektar Therapeutics, H2 2012 101
Gilead Sciences, Inc., H2 2012 102
Daiichi Sankyo Company, Ltd, H2 2012 103
AbGenomics International, Inc., H2 2012 104
Oxford BioMedica plc, H2 2012 105
YM BioSciences Inc., H2 2012 106
Celltrion, Inc., H2 2012 107
BioSante Pharmaceuticals, Inc., H2 2012 108
Novartis AG, H2 2012 109
Aphios Corporation, H2 2012 110
Astellas Pharma Inc., H2 2012 111
Chong Kun Dang Pharmaceutical, H2 2012 112
Eisai Co., Ltd., H2 2012 113
Nippon Kayaku Co., Ltd., H2 2012 114
Taiho Pharmaceutical Co., Ltd., H2 2012 115
Teva Pharmaceutical Industries Limited, H2 2012 116
Yakult Honsha Co., Ltd., H2 2012 117
Cell Therapeutics, Inc., H2 2012 118
Enzon Pharmaceuticals, Inc., H2 2012 119
Santaris Pharma A/S, H2 2012 120
Bayer AG, H2 2012 121
4SC AG, H2 2012 122
Neogenix Oncology Corporation, H2 2012 123
EntreMed, Inc., H2 2012 124
Celldex Therapeutics, Inc., H2 2012 125
Enzo Biochem, Inc., H2 2012 126
AEterna Zentaris Inc., H2 2012 127
IMMUNOMEDICS, INC, H2 2012 128
Neuren Pharmaceuticals Limited, H2 2012 129
Novogen Limited, H2 2012 130
Oncolytics Biotech Inc., H2 2012 131
Compugen Ltd., H2 2012 132
Critical Outcome Technologies Inc., H2 2012 133
Telik, Inc., H2 2012 134
Poniard Pharmaceuticals, Inc., H2 2012 135

List of Chart


Number of Products under Development for Colorectal Cancer, H2 2012 20
Products under Development for Colorectal Cancer Comparative Analysis, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 30
Late Stage Products, H2 2012 46
Mid Clinical Stage Products, H2 2012 47
Early Clinical Stage Products, H2 2012 48
Discovery and Pre-Clinical Stage Products, H2 2012 49
Assessment by Monotherapy Products, H2 2012 176
Assessment by Combination Products, H2 2012 177
Assessment by Route of Administration, H2 2012 178
Assessment by Stage and Route of Administration, H2 2012 179
Assessment by Molecule Type, H2 2012 180
Assessment by Stage and Molecule Type, H2 2012 181

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *